Marc Cloutier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marc Cloutier has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Sonia Néron
Medical Affairs and Innovation, Héma-Québec, Québec, Quebec, Canada
6 shared publications - Sandra Ramirez‐Arcos
Medical Microbiology Canadian Blood Services Ottawa Ontario Canada
5 shared publications - Bruno Piedboeuf
Department of Paediatrics, University Laval, Faculty of Medicine, Quebec City, Quebec
4 shared publications - Carl McDonald
National Health Service Blood and Transplant London UK
4 shared publications Tanja Vollmer
Institut für Laboratoriums‐ und Transfusionsmedizin, Herz‐ und Diabeteszentrum NRW Universitätsklinik der Ruhr‐Universität Bochum Bad Oeynhausen Germany
4 shared publicationsCarl Simard
Medical Affairs and Innovation, Héma-Québec, 1070 avenue des Sciences-de-la-Vie, Québec, Québec G1V 5C3, Canada
3 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Vox Sanguinis
From contamination to fever: The role of endotoxin levels in bacterially contaminated platelet concentrates
Background and Objectives: Growth of gram‐negative bacteria in a platelet concentrate (PC) is inevitably accompanied by the accumulation of endotoxin, which is the major component of the outer cell membrane of these organisms. However, less is known about the kinetics of endotoxin accumulation in PC and its biological activity. Therefore, the endotoxin level of Klebsiella pneumoniae contaminated PCs was measured over time. In addition, the biological activity of the contaminants was analysed by an assay that mimics the human fever response in vitro. Materials and Methods: The bacterial endotoxin test and the monocyte activation test were established for PC samples for endotoxin and pyrogen detection, respectively. Low‐count spiking of PCs using K. pneumoniae PEI‐B‐P‐08 was performed by six laboratories, and samples were taken over time. The samples were analysed for the number of viable cells, the amount of endotoxin and their capacity to induce the production of fever‐inducing cytokine interleukin 6 (IL‐6). Results: K. pneumoniae showed fast proliferation in contaminated PCs reaching stationary phase 36 h post‐spiking. Endotoxin was measurable in samples with a bacterial load of more than 10 3 CFU/mL and increased proportionally to the number of bacteria present. IL‐6 production was found to be linked to endotoxin levels in PCs reaching levels of high pyrogenicity 24 h post‐spiking. Conclusion: PCs contaminated with more than 10 3 CFU/mL of K. pneumoniae might be a risk for patients due to their ability to induce pyrogenic reactions during transfusion.
- 22 October 2026
- Published by Wiley in Vox Sanguinis
Open AccessFrom contamination to fever: The role of endotoxin levels in bacterially contaminated platelet concentrates
Background and Objectives: Growth of gram‐negative bacteria in a platelet concentrate (PC) is inevitably accompanied by the accumulation of endotoxin, which is the major component of the outer cell membrane of these organisms. However, less is known about the kinetics of endotoxin accumulation in PC and its biological activity. Therefore, the endotoxin level of Klebsiella pneumoniae contaminated PCs was measured over time. In addition, the biological activity of the contaminants was analysed by an assay that mimics the human fever response in vitro. Materials and Methods: The bacterial endotoxin test and the monocyte activation test were established for PC samples for endotoxin and pyrogen detection, respectively. Low‐count spiking of PCs using K. pneumoniae PEI‐B‐P‐08 was performed by six laboratories, and samples were taken over time. The samples were analysed for the number of viable cells, the amount of endotoxin and their capacity to induce the production of fever‐inducing cytokine interleukin 6 (IL‐6). Results: K. pneumoniae showed fast proliferation in contaminated PCs reaching stationary phase 36 h post‐spiking. Endotoxin was measurable in samples with a bacterial load of more than 10 3 CFU/mL and increased proportionally to the number of bacteria present. IL‐6 production was found to be linked to endotoxin levels in PCs reaching levels of high pyrogenicity 24 h post‐spiking. Conclusion: PCs contaminated with more than 10 3 CFU/mL of K. pneumoniae might be a risk for patients due to their ability to induce pyrogenic reactions during transfusion.
- 10 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2195-2203
Relevance of circulating IgG levels as a marker of health in plasma donors
Background: Frequent plasma donation is associated with reduced circulating IgG levels, prompting many jurisdictions to apply IgG‐based deferral thresholds as a precautionary donor‐safety measure. However, whether low IgG in healthy individuals reflects clinically meaningful immunosuppression remains unclear. This study evaluated IgG as a marker for donor health by integrating immunological, behavioral and self‐reported outcomes, including vaccine responses, return to donation, and health problems. Study Design and Methods: The kinetics of IgG decline associated with frequent plasma donation were analyzed over 18 months in 49 first‐time and 50 repeat donors. Vaccine responses were evaluated in repeat donors with low or high IgG using ELISA to measure SARS‐CoV‐2 Spike receptor‐binding domain antibodies and avidity after primary and booster COVID‐19 vaccination. Return to plasma donation was examined in 3897 first‐time plasma donors followed up to 22 months. Self‐reported health problems were analyzed in 5347 plasma donors over 10 years. Results: IgG levels declined during early donations in first‐time donors but stabilized thereafter, suggesting a new homeostatic set point rather than progressive IgG depletion. All vaccinated donors seroconverted after primary vaccination regardless of IgG level. Although antibody levels were slightly lower in low‐IgG donors, affinity maturation was comparable after boosting. IgG levels were not associated with return to donation or increased self‐reported health problems. Discussion: Low IgG levels in healthy plasma donors were not associated with impaired immunity, donor retention, or increased self‐reported health problems. These findings support cautious interpretation of isolated IgG values in donor management and favor longitudinal monitoring over fixed thresholds.
- 10 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2195-2203
Relevance of circulating IgG levels as a marker of health in plasma donors
Background: Frequent plasma donation is associated with reduced circulating IgG levels, prompting many jurisdictions to apply IgG‐based deferral thresholds as a precautionary donor‐safety measure. However, whether low IgG in healthy individuals reflects clinically meaningful immunosuppression remains unclear. This study evaluated IgG as a marker for donor health by integrating immunological, behavioral and self‐reported outcomes, including vaccine responses, return to donation, and health problems. Study Design and Methods: The kinetics of IgG decline associated with frequent plasma donation were analyzed over 18 months in 49 first‐time and 50 repeat donors. Vaccine responses were evaluated in repeat donors with low or high IgG using ELISA to measure SARS‐CoV‐2 Spike receptor‐binding domain antibodies and avidity after primary and booster COVID‐19 vaccination. Return to plasma donation was examined in 3897 first‐time plasma donors followed up to 22 months. Self‐reported health problems were analyzed in 5347 plasma donors over 10 years. Results: IgG levels declined during early donations in first‐time donors but stabilized thereafter, suggesting a new homeostatic set point rather than progressive IgG depletion. All vaccinated donors seroconverted after primary vaccination regardless of IgG level. Although antibody levels were slightly lower in low‐IgG donors, affinity maturation was comparable after boosting. IgG levels were not associated with return to donation or increased self‐reported health problems. Discussion: Low IgG levels in healthy plasma donors were not associated with impaired immunity, donor retention, or increased self‐reported health problems. These findings support cautious interpretation of isolated IgG values in donor management and favor longitudinal monitoring over fixed thresholds.
- 14 March 2025
- Published by Wiley in Transfusion
- Vol. 65 (4) , 732-739
Automated processing of Meryman‐frozen red blood cells: A novel protocol for deglycerolization
Background: Many blood services maintain large inventories of red blood cell (RBC) units cryopreserved in glycerol using the Meryman method. With the discontinuation of the COBE® 2991 cell processor, an alternative thawing method is needed. We aimed to develop a deglycerolization protocol for Meryman‐frozen units using the ACP® 215 cell washer.Methods: In the optimization phase, Meryman‐frozen RBC units stored for 10 years were thawed, paired, and divided into two groups: one with a centrifugation step to remove glycerol before deglycerolization (“volume reduction”) and one without. Biochemical and hematological parameters assessed included hemolysis, hematocrit, hemoglobin, ATP, pH, and osmolality. The protocol was then validated.Results: Hemolysis rates were lower with than without volume reduction (0.4% vs. 0.6%). Centrifuged RBCs also showed higher recovery (72% vs. 63%), increased hematocrit (0.51 L/L vs. 0.40 L/L), and improved pH stability (6.17 vs. 6.11). In the validation phase, six RBC units deglycerolized using the volume reduction step met Canadian Standards Association requirements for hematocrit, hemoglobin, hemolysis, and sterility.Discussion: We optimized and validated a new protocol leveraging the ACP® 215 cell washer to deglycerolize Meryman‐frozen RBCs. This method yielded low hemolysis, acceptable pH, and satisfactory recovery, especially with prior glycerol removal by centrifugation. The protocol has been successfully implemented, and Meryman‐frozen RBC units have since been reliably thawed, meeting regulatory standards and supporting hospital needs.
- 14 March 2025
- Published by Wiley in Transfusion
- Vol. 65 (4) , 732-739
Automated processing of Meryman‐frozen red blood cells: A novel protocol for deglycerolization
Background: Many blood services maintain large inventories of red blood cell (RBC) units cryopreserved in glycerol using the Meryman method. With the discontinuation of the COBE® 2991 cell processor, an alternative thawing method is needed. We aimed to develop a deglycerolization protocol for Meryman‐frozen units using the ACP® 215 cell washer.Methods: In the optimization phase, Meryman‐frozen RBC units stored for 10 years were thawed, paired, and divided into two groups: one with a centrifugation step to remove glycerol before deglycerolization (“volume reduction”) and one without. Biochemical and hematological parameters assessed included hemolysis, hematocrit, hemoglobin, ATP, pH, and osmolality. The protocol was then validated.Results: Hemolysis rates were lower with than without volume reduction (0.4% vs. 0.6%). Centrifuged RBCs also showed higher recovery (72% vs. 63%), increased hematocrit (0.51 L/L vs. 0.40 L/L), and improved pH stability (6.17 vs. 6.11). In the validation phase, six RBC units deglycerolized using the volume reduction step met Canadian Standards Association requirements for hematocrit, hemoglobin, hemolysis, and sterility.Discussion: We optimized and validated a new protocol leveraging the ACP® 215 cell washer to deglycerolize Meryman‐frozen RBCs. This method yielded low hemolysis, acceptable pH, and satisfactory recovery, especially with prior glycerol removal by centrifugation. The protocol has been successfully implemented, and Meryman‐frozen RBC units have since been reliably thawed, meeting regulatory standards and supporting hospital needs.
- Open Access
- 16 May 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (8) , 834-841
Characterization of transfusion‐relevant bacteria reference strains in a lyophilized format
Background and Objectives: Blood safety measures used by blood establishments to increase blood component safety can be validated using Transfusion‐Relevant Bacterial Reference Strains (TRBRS). Ultra‐cold storage conditions and manual preparation of the current TRBRS may restrict their practical use. To address this issue, the ISBT Transfusion‐Transmitted Infectious Diseases Working Party's Bacterial Subgroup organized an international study to validate TRBRS in a user‐friendly, lyophilised format.Materials and Methods: Two bacterial strains Klebsiella pneumoniae PEI‐B‐P‐08 and Staphylococcus aureus PEI‐B‐P‐63 were manufactured as lyophilised material. The lyophilised bacteria were distributed to 11 different labs worldwide to assess the robustness for enumeration, identification and determination of growth kinetics in platelet concentrates (PCs).Results: Production of lyophilised TRBRS had no impact on the growth properties compared with the traditional format. The new format allows a direct low‐quantity spiking of approximately 30 bacteria in PCs for transfusion‐relevant experiments. In addition, the lyophilised bacteria exhibit long‐term stability across a broad temperature range and can even be directly rehydrated in PCs without losing viability. Interlaboratory comparative study demonstrated the robustness of the new format as 100% of spiked PC exhibited growth.Conclusion: Lyophilised TRBRS provide a user‐friendly material for transfusion‐related studies. TRBRS in the new format have improved features that may lead to a more frequent use in the quality control of transfusion‐related safety measures in the future.
- 16 May 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (8) , 834-841
Open AccessCharacterization of transfusion‐relevant bacteria reference strains in a lyophilized format
Background and Objectives: Blood safety measures used by blood establishments to increase blood component safety can be validated using Transfusion‐Relevant Bacterial Reference Strains (TRBRS). Ultra‐cold storage conditions and manual preparation of the current TRBRS may restrict their practical use. To address this issue, the ISBT Transfusion‐Transmitted Infectious Diseases Working Party's Bacterial Subgroup organized an international study to validate TRBRS in a user‐friendly, lyophilised format.Materials and Methods: Two bacterial strains Klebsiella pneumoniae PEI‐B‐P‐08 and Staphylococcus aureus PEI‐B‐P‐63 were manufactured as lyophilised material. The lyophilised bacteria were distributed to 11 different labs worldwide to assess the robustness for enumeration, identification and determination of growth kinetics in platelet concentrates (PCs).Results: Production of lyophilised TRBRS had no impact on the growth properties compared with the traditional format. The new format allows a direct low‐quantity spiking of approximately 30 bacteria in PCs for transfusion‐relevant experiments. In addition, the lyophilised bacteria exhibit long‐term stability across a broad temperature range and can even be directly rehydrated in PCs without losing viability. Interlaboratory comparative study demonstrated the robustness of the new format as 100% of spiked PC exhibited growth.Conclusion: Lyophilised TRBRS provide a user‐friendly material for transfusion‐related studies. TRBRS in the new format have improved features that may lead to a more frequent use in the quality control of transfusion‐related safety measures in the future.
- Open Access
- 17 April 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (7) , 693-701
Proliferation of psychrotrophic bacteria in cold‐stored platelet concentrates
Background and Objectives: Platelet concentrates (PC) are stored at 20–24°C to maintain platelet functionality, which may promote growth of contaminant bacteria. Alternatively, cold storage of PC limits bacterial growth; however, data related to proliferation of psychotrophic species in cold‐stored PC (CSP) are scarce, which is addressed in this study.Materials and Methods: Eight laboratories participated in this study with a pool/split approach. Two split PC units were spiked with ~25 colony forming units (CFU)/PC of Staphylococcus aureus, Klebsiella pneumoniae, Serratia liquefaciens, Pseudomonas fluorescens and Listeria monocytogenes. One unit was stored under agitation at 20–24°C/7 days while the second was stored at 1–6°C/no agitation for 21 days. PC were sampled periodically to determine bacterial loads. Five laboratories repeated the study with PC inoculated with lyophilized inocula (~30 CFU/mL) of S. aureus and K. pneumoniae.Results: All species proliferated in PC stored at 20–24°C, reaching concentrations of ≤109 CFU/mL by day 7. Psychrotrophic P. fluorescens and S. liquefaciens proliferated in CSP to ~106 CFU/mL and ~105 CFU/mL on days 10 and 17 of storage, respectively, followed by L. monocytogenes, which reached ~102 CFU/mL on day 21. S. aureus and K. pneumoniae did not grow in CSP.Conclusion: Psychrotrophic bacteria, which are relatively rare contaminants in PC, proliferated in CSP, with P. fluorescens reaching clinically significant levels (≥105 CFU/mL) before day 14 of storage. Cold storage reduces bacterial risk of PC to levels comparable with RBC units. Safety of CSP could be further improved by implementing bacterial detection systems or pathogen reduction technologies if storage is beyond 10 days.
- 17 April 2024
- Published by Wiley in Vox Sanguinis
- Vol. 119 (7) , 693-701
Open AccessProliferation of psychrotrophic bacteria in cold‐stored platelet concentrates
Background and Objectives: Platelet concentrates (PC) are stored at 20–24°C to maintain platelet functionality, which may promote growth of contaminant bacteria. Alternatively, cold storage of PC limits bacterial growth; however, data related to proliferation of psychotrophic species in cold‐stored PC (CSP) are scarce, which is addressed in this study.Materials and Methods: Eight laboratories participated in this study with a pool/split approach. Two split PC units were spiked with ~25 colony forming units (CFU)/PC of Staphylococcus aureus, Klebsiella pneumoniae, Serratia liquefaciens, Pseudomonas fluorescens and Listeria monocytogenes. One unit was stored under agitation at 20–24°C/7 days while the second was stored at 1–6°C/no agitation for 21 days. PC were sampled periodically to determine bacterial loads. Five laboratories repeated the study with PC inoculated with lyophilized inocula (~30 CFU/mL) of S. aureus and K. pneumoniae.Results: All species proliferated in PC stored at 20–24°C, reaching concentrations of ≤109 CFU/mL by day 7. Psychrotrophic P. fluorescens and S. liquefaciens proliferated in CSP to ~106 CFU/mL and ~105 CFU/mL on days 10 and 17 of storage, respectively, followed by L. monocytogenes, which reached ~102 CFU/mL on day 21. S. aureus and K. pneumoniae did not grow in CSP.Conclusion: Psychrotrophic bacteria, which are relatively rare contaminants in PC, proliferated in CSP, with P. fluorescens reaching clinically significant levels (≥105 CFU/mL) before day 14 of storage. Cold storage reduces bacterial risk of PC to levels comparable with RBC units. Safety of CSP could be further improved by implementing bacterial detection systems or pathogen reduction technologies if storage is beyond 10 days.
- Open Access
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
SUMMARY: COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, specific CCP characteristics that promote SARS-CoV-2 control in recipients are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing and high Fc-effector activity, in contrast to those with poor Fc-function, afford effective prophylaxis and therapy in K18-hACE2 mice lethally challenged with SARS-CoV-2-nLuc. Macrophages and neutrophils significantly contributed to CCP effects during therapy but to a reduced extent under prophylaxis. Both IgG and Ig(M+A) were required during therapy, but the IgG fraction alone was sufficient during prophylaxis. Finally, despite neutralizing poorly, SARS-CoV-2 Wuhan-elicited CCPs delayed Delta and Beta variants of concern (VOC)-induced mortality in mice illustrating the contribution of polyclonal Fc-effector functions in immunity against VOCs. Thus, in addition to neutralization, Fc-effector activity is a significant criterion for CCP selection for therapeutic applications.
Open AccessThe Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
SUMMARY: COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, specific CCP characteristics that promote SARS-CoV-2 control in recipients are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing and high Fc-effector activity, in contrast to those with poor Fc-function, afford effective prophylaxis and therapy in K18-hACE2 mice lethally challenged with SARS-CoV-2-nLuc. Macrophages and neutrophils significantly contributed to CCP effects during therapy but to a reduced extent under prophylaxis. Both IgG and Ig(M+A) were required during therapy, but the IgG fraction alone was sufficient during prophylaxis. Finally, despite neutralizing poorly, SARS-CoV-2 Wuhan-elicited CCPs delayed Delta and Beta variants of concern (VOC)-induced mortality in mice illustrating the contribution of polyclonal Fc-effector functions in immunity against VOCs. Thus, in addition to neutralization, Fc-effector activity is a significant criterion for CCP selection for therapeutic applications.
- 21 March 2022
- Published by Wiley in Vox Sanguinis
- Vol. 117 (7) , 879-886
Residual risks of bacterial contamination for pathogen‐reduced platelet components
Platelet components are commonly transfused to patients for a variety of indications, including patients with low platelet counts or patients with platelet dysfunction who are bleeding or at high risk of bleeding. Although the risk of pathogen contamination of platelet components has declined significantly over the last 40 years, it remains a concern for the patients, for blood banks and for physicians. Pathogen inactivation (PI) technologies have been developed to mitigate this risk. This review focuses on the residual risks of transfusion‐transmitted bacterial infections by platelet transfusion after PI. We describe and assess the relationship between the bacterial load and the timing and capacity of reduction of the different PI technologies, as well as the risks that could represent spore‐forming microorganisms and the possible introduction of microorganisms after PI.
- 21 March 2022
- Published by Wiley in Vox Sanguinis
- Vol. 117 (7) , 879-886
Residual risks of bacterial contamination for pathogen‐reduced platelet components
Platelet components are commonly transfused to patients for a variety of indications, including patients with low platelet counts or patients with platelet dysfunction who are bleeding or at high risk of bleeding. Although the risk of pathogen contamination of platelet components has declined significantly over the last 40 years, it remains a concern for the patients, for blood banks and for physicians. Pathogen inactivation (PI) technologies have been developed to mitigate this risk. This review focuses on the residual risks of transfusion‐transmitted bacterial infections by platelet transfusion after PI. We describe and assess the relationship between the bacterial load and the timing and capacity of reduction of the different PI technologies, as well as the risks that could represent spore‐forming microorganisms and the possible introduction of microorganisms after PI.
- 1 February 2021
- Published by Wiley in ISBT Science Series
- Vol. 16 (1) , 119-126
Prediction of donation return rate in young donors using machine‐learning models
- 1 February 2021
- Published by Wiley in ISBT Science Series
- Vol. 16 (1) , 119-126
Prediction of donation return rate in young donors using machine‐learning models
- Open Access
- 20 December 2020
- Published by Wiley in Vox Sanguinis
- Vol. 116 (6) , 692-701
Establishment of transfusion‐relevant bacteria reference strains for red blood cells
Background and objectives: Red blood cell concentrates (RBCC) are susceptible to bacterial contamination despite cold storage. A reliable evaluation of strategies to minimize the risk of RBCC‐associated bacterial transmission requires the use of suitable reference bacteria. Already existing Transfusion‐Relevant Bacteria Reference Strains (TRBRS) for platelet concentrates fail to grow in RBCC. Consequently, the ISBT TTID, Working Party, Bacterial Subgroup, conducted an international study on TRBRS for RBCC.Materials and methods: Six bacterial strains (Listeria monocytogenes PEI‐A‐199, Serratia liquefaciens PEI‐A‐184, Serratia marcescens PEI‐B‐P‐56, Pseudomonas fluorescens PEI‐B‐P‐77, Yersinia enterocolitica PEI‐A‐105, Yersinia enterocolitica PEI‐A‐176) were distributed to 15 laboratories worldwide for enumeration, identification, and determination of growth kinetics in RBCC at days 7, 14, 21, 28, 35 and 42 of storage after low‐count spiking (10–25 CFU/RBCC).Results: Bacterial proliferation in RBCC was obtained for most strains, except for S. marcescens, which grew only at 4 of 15 laboratories. S. liquefaciens, S. marcescens, P. fluorescens and the two Y. enterocolitica strains reached the stationary phase between days 14 and 21 of RBCC storage with a bacterial concentration of approximately 109 CFU/ml. L. monocytogenes displayed slower growth kinetics reaching 106–107 CFU/ml after 42 days.Conclusion: The results illustrate the importance of conducting comprehensive studies to establish well‐characterized reference strains, which can be a tool to assess strategies and methods used to ameliorate blood safety. The WHO Expert Committee on Biological Standardization adopted the five successful strains as official RBCC reference strains. Our study also highlights the relevance of visual inspection to interdict contaminated RBC units.
- 20 December 2020
- Published by Wiley in Vox Sanguinis
- Vol. 116 (6) , 692-701
Open AccessEstablishment of transfusion‐relevant bacteria reference strains for red blood cells
Background and objectives: Red blood cell concentrates (RBCC) are susceptible to bacterial contamination despite cold storage. A reliable evaluation of strategies to minimize the risk of RBCC‐associated bacterial transmission requires the use of suitable reference bacteria. Already existing Transfusion‐Relevant Bacteria Reference Strains (TRBRS) for platelet concentrates fail to grow in RBCC. Consequently, the ISBT TTID, Working Party, Bacterial Subgroup, conducted an international study on TRBRS for RBCC.Materials and methods: Six bacterial strains (Listeria monocytogenes PEI‐A‐199, Serratia liquefaciens PEI‐A‐184, Serratia marcescens PEI‐B‐P‐56, Pseudomonas fluorescens PEI‐B‐P‐77, Yersinia enterocolitica PEI‐A‐105, Yersinia enterocolitica PEI‐A‐176) were distributed to 15 laboratories worldwide for enumeration, identification, and determination of growth kinetics in RBCC at days 7, 14, 21, 28, 35 and 42 of storage after low‐count spiking (10–25 CFU/RBCC).Results: Bacterial proliferation in RBCC was obtained for most strains, except for S. marcescens, which grew only at 4 of 15 laboratories. S. liquefaciens, S. marcescens, P. fluorescens and the two Y. enterocolitica strains reached the stationary phase between days 14 and 21 of RBCC storage with a bacterial concentration of approximately 109 CFU/ml. L. monocytogenes displayed slower growth kinetics reaching 106–107 CFU/ml after 42 days.Conclusion: The results illustrate the importance of conducting comprehensive studies to establish well‐characterized reference strains, which can be a tool to assess strategies and methods used to ameliorate blood safety. The WHO Expert Committee on Biological Standardization adopted the five successful strains as official RBCC reference strains. Our study also highlights the relevance of visual inspection to interdict contaminated RBC units.
- Open Access
- 6 February 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (6) , 441-448
Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation
The rare PEL-negative phenotype is one of the last blood groups with an unknown genetic basis. By combining whole-exome sequencing and comparative global proteomic investigations, we found a large deletion in the ABCC4/MRP4 gene encoding an ATP-binding cassette (ABC) transporter in PEL-negative individuals. The loss of PEL expression on ABCC4-CRISPR-Cas9 K562 cells and its overexpression in ABCC4-transfected cells provided evidence that ABCC4 is the gene underlying the PEL blood group antigen. Although ABCC4 is an important cyclic nucleotide exporter, red blood cells from ABCC4null/PEL-negative individuals exhibited a normal guanosine 3′,5′-cyclic monophosphate level, suggesting a compensatory mechanism by other erythroid ABC transporters. Interestingly, PEL-negative individuals showed an impaired platelet aggregation, confirming a role for ABCC4 in platelet function. Finally, we showed that loss-of-function mutations in the ABCC4 gene, associated with leukemia outcome, altered the expression of the PEL antigen. In addition to ABCC4 genotyping, PEL phenotyping could open a new way toward drug dose adjustment for leukemia treatment.
- 6 February 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (6) , 441-448
Open AccessLack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation
The rare PEL-negative phenotype is one of the last blood groups with an unknown genetic basis. By combining whole-exome sequencing and comparative global proteomic investigations, we found a large deletion in the ABCC4/MRP4 gene encoding an ATP-binding cassette (ABC) transporter in PEL-negative individuals. The loss of PEL expression on ABCC4-CRISPR-Cas9 K562 cells and its overexpression in ABCC4-transfected cells provided evidence that ABCC4 is the gene underlying the PEL blood group antigen. Although ABCC4 is an important cyclic nucleotide exporter, red blood cells from ABCC4null/PEL-negative individuals exhibited a normal guanosine 3′,5′-cyclic monophosphate level, suggesting a compensatory mechanism by other erythroid ABC transporters. Interestingly, PEL-negative individuals showed an impaired platelet aggregation, confirming a role for ABCC4 in platelet function. Finally, we showed that loss-of-function mutations in the ABCC4 gene, associated with leukemia outcome, altered the expression of the PEL antigen. In addition to ABCC4 genotyping, PEL phenotyping could open a new way toward drug dose adjustment for leukemia treatment.